Question 1

Has Ann Mullally received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $1,361,079 in general payments to Ann Mullally across 43 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Ann Mullally did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Ann Mullally come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Janssen Research & Development, LLC	9	$540,475
Incyte Corporation	21	$450,205
Johnson & Johnson	2	$358,000
Pharmaessentia USA Corporation	5	$7,368
F. Hoffmann-la Roche AG	3	$2,940
Biomarin Pharmaceutical Inc.	1	$1,200
Genentech, Inc.	2	$892

Ann Mullally

Payments from drug & device makers

Who reported the general payments

What the payments were tied to

How this compares

Other hematology & oncology in Stanford